Epi Biotech Co., Ltd.

As of December 31, 2025, Epi Biotech Co., Ltd. carries a market capitalization of 34.60B, placing it among publicly traded companies globally. Its enterprise value stands at 33.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Epi Biotech Co., Ltd. has 2.31M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 17.93, and the price-to-book ratio stands at -2.91.

These figures are as of December 31, 2025. The EV/Sales ratio of 17.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 33.90B versus a market cap of 34.60B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Epi Biotech Co., Ltd. maintains a current ratio of 0.18, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.06, indicating conservative leverage, while an interest coverage ratio of -0.69 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -42.85, reflecting losses generated across the asset base. The company generates approximately 83.86M in revenue per employee across its workforce of 23.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.46 indicates how many times Epi Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Epi Biotech Co., Ltd.'s stock has gained approximately 22.70% over the past 52 weeks. The 50-day moving average sits at 15,156.80, while the 200-day moving average is 14,587.10.

Over the twelve months ended December 31, 2025, Epi Biotech Co., Ltd. generated 1.93B in revenue and converted that into -1.91B in net income, yielding earnings per share of -828.56. EBITDA reached -967.06M, while operating income came in at -1.49B.

As of December 31, 2025, Epi Biotech Co., Ltd. holds 2.62B in cash and equivalents against 1.91B in total debt, resulting in a net debt position of -686.90M. Total book value stands at -11.90B, with working capital of -13.62B providing operational flexibility.

Epi Biotech Co., Ltd. produced -662.88M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -101.68M in capital expenditures, free cash flow totaled -764.57M - equivalent to -331.72 per share.

Over the twelve months ended December 31, 2025, Epi Biotech Co., Ltd. posted a gross margin of 87.26, reflecting its pricing power and cost economics. The operating margin of -77.07 and net profit margin of -99.01 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -2.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.61, meaning Epi Biotech Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Epi Biotech Co., Ltd. has an Altman Z-Score of -7.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.